explore -WSS

explore

author：explore 2025-10-01 00:46:11 - browse：95

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： US soldier in North Korean custody after crossing DMZ line

Wikipedia

focus

WSS

What we know about the American soldier detained in North Korea

How the political right came to back psychedelics to treat trauma

House passes resolution saying Israel isn't a 'racist or apartheid state'

HCA discloses massive data breach affecting 11 million patients

Oak trusses raised to roof of fire

A look at other Americans who have crossed into North Korea over the years

leisure time

explore

focus

Alkermes shareholders re

Bulgari apologizes to China for listing Taiwan as a country after online backlash

DIEP, the 'gold standard' of breast reconstruction, is under threat

Johnson & Johnson sues to stop Medicare negotiation

Walensky prepares to leave CDC — and Congress — behind

FDA seeking to stop procedures at two unregulated stem cell clinics

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

UK homeowners get some respite as inflation falls by more than anticipated to a 15

As demand for Covid shots wanes, Moderna seeks its next success

Why you get paid to donate plasma but not blood

hotspot

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

N.Y. state detects polio case, first in the U.S. since 2013

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Lack of darker skin in textbooks, journals harms patients of color

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Elizabeth Holmes on track for early release from her 11

Wikipedia

focus

focus

knowledge